Jackie Maxey
Family Medicine · London, KYNPI 1073525861
Payments from drug & device makers
Across 810 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Pfizer$1K
- Boehringer Ingelheim$1K
- Novartis$1K
- Novo Nordisk$771
- plus $5K from 37 others
What the payments were for
- Food & beverage$12,074100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,111 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 900 | $356,373 |
| MounjaroTirzepatide | 222 | $238,411 |
| OzempicSemaglutide | 193 | $187,922 |
| TrulicityDulaglutide | 103 | $145,087 |
| LinzessLinaclotide | 169 | $107,425 |
| FarxigaDapagliflozin Propanediol | 114 | $104,941 |
| JanuviaSitagliptin Phosphate | 140 | $103,144 |
| JardianceEmpagliflozin | 110 | $99,382 |
| XareltoRivaroxaban | 212 | $90,796 |
| NuplazidPimavanserin Tartrate | 13 | $64,940 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $50,053 |
| EntrestoSacubitril/Valsartan | 102 | $48,628 |
| RexultiBrexpiprazole | 24 | $33,701 |
| Tresiba Flextouch U-100Insulin Degludec | 122 | $31,448 |
| TradjentaLinagliptin | 39 | $30,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,277 | $383,498325 claims |
| PfizerEliquis | $1,269 | $356,373900 claims |
| Novo NordiskOzempic, Wegovy | $771 | $203,834205 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $1,128 | $177,678234 claims |
| AbbVieLinzess, Creon, Vraylar | $323 | $162,890206 claims |
| AstraZenecaFarxiga, Brilinta | $1,516 | $129,702162 claims |
| MerckJanuvia | $497 | $103,144140 claims |
| Johnson & JohnsonXarelto | $18 | $90,796212 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $404 | $82,594144 claims |
| NovartisEntresto | $1,121 | $48,628102 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $69 | $33,70124 claims |
| Sanofi-aventis U.S. LLCMultaq | $216 | $11,22619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in London
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.